Experienced in Transient Erythroblastopenia of Childhood

Dr. Laura Michaelis

Hematology
Cancer Center-Moorland Reserve Health Center
4805 S Moorland Rd, 
New Berlin, WI 
Offers Telehealth
Experienced in Transient Erythroblastopenia of Childhood
Cancer Center-Moorland Reserve Health Center
4805 S Moorland Rd, 
New Berlin, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Laura Michaelis is a Hematologist in New Berlin, Wisconsin. Dr. Michaelis is rated as an Experienced provider by MediFind in the treatment of Transient Erythroblastopenia of Childhood. Her top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPN), Acute Myeloblastic Leukemia without Maturation, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 59 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in IL
Hospital Affiliations
Froedtert Memorial Lutheran Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Cancer Center-Moorland Reserve Health Center
4805 S Moorland Rd, New Berlin, WI 53151
Other Locations
Clinical Cancer Center-Froedtert Hospital
8800 W Doyne Ave, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)
Enrollment Status: Completed
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: CPI-0610, Rituximab
Study Phase: Phase 1/Phase 2
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension Study.
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2025
Intervention Type: Drug, Biological
Study Drug: PEG-IFN-Alpha-2b
Study Phase: Phase 3
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Enrollment Status: Completed
Publish Date: January 16, 2025
Intervention Type: Drug, Biological, Other
Study Drugs: Azacitidine, Cytarabine, Decitabine, Midostaurin, Nivolumab
Study Phase: Phase 2/Phase 3
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: August 27, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea
A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF), Post-Essential Thrombocythemia MF (PET-MF), MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea
Enrollment Status: Completed
Publish Date: June 27, 2024
Intervention Type: Drug
Study Drugs: TGR-1202 PI3K Delta Inhibitor, Ruxolitinib
Study Phase: Phase 1
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Enrollment Status: Terminated
Publish Date: January 30, 2024
Intervention Type: Biological, Drug
Study Drug: Flotetuzumab
Study Phase: Phase 1/Phase 2
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Poor-Risk Acute Myelogenous Leukemia
S0919, A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Poor-Risk Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: May 03, 2023
Intervention Type: Drug
Study Drugs: Cytarabine, Idarubicin, Pravastatin
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
An Open-Label Phase I/II Study of Bendamustine, Weekly Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
An Open-Label Phase I/II Study of Bendamustine, Weekly Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: July 10, 2018
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

59 Total Publications

Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.
Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.
Journal: Leukemia
Published: October 31, 2024
Similar Doctors
Experienced in Transient Erythroblastopenia of Childhood
Dr. Walter Longo
Hematology
Experienced in Transient Erythroblastopenia of Childhood
Dr. Walter Longo
Hematology

Cancer Center-Moorland Reserve Health Center

4805 S Moorland Rd, 
New Berlin, WI 
 (0.1 miles away)
414-805-0505
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Walter Longo is a Hematologist in New Berlin, Wisconsin. Dr. Longo is rated as a Distinguished provider by MediFind in the treatment of Transient Erythroblastopenia of Childhood. His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Transplant, and Bone Marrow Aspiration.

Experienced in Transient Erythroblastopenia of Childhood
Dr. Patrick Foy Jr
Hematology
Experienced in Transient Erythroblastopenia of Childhood
Dr. Patrick Foy Jr
Hematology

Cancer Center-Froedtert West Bend Hospital

3200 Pleasant Valley Rd, 
West Bend, WI 
 (27.9 miles away)
262-836-7200
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Patrick Foy Jr is a Hematologist in West Bend, Wisconsin. Dr. Foy Jr is rated as a Distinguished provider by MediFind in the treatment of Transient Erythroblastopenia of Childhood. His top areas of expertise are Hereditary Hemorrhagic Telangiectasia, MAGIC Syndrome, Monoclonal Gammopathy of Undetermined Significance (MGUS), Schnitzler Syndrome, and Bone Marrow Aspiration.

Experienced in Transient Erythroblastopenia of Childhood
Dr. Ehab Atallah
Hematology
Experienced in Transient Erythroblastopenia of Childhood
Dr. Ehab Atallah
Hematology

Cancer Center-Moorland Reserve Health Center

4805 S Moorland Rd, 
New Berlin, WI 
 (0.1 miles away)
414-805-0505
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ehab Atallah is a Hematologist in New Berlin, Wisconsin. Dr. Atallah is rated as an Elite provider by MediFind in the treatment of Transient Erythroblastopenia of Childhood. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Michaelis's expertise for a condition
ConditionClose
View All 20 Advanced Conditions
View All 30 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile